HI-Bio
Recent Finacing
Series B
Recent Raise
$95M
Human Immunology Biosciences is a clinical-stage San Francisco biotech developing precision therapeutics for immune-mediated diseases, advancing in-licensed anti-CD38 felzartamab across autoimmune kidney indications and anti-C5aR1 HIB210.
Highlights
Focus Areas
Biotechnology
Life Science
Medical
Product Research
Therapeutics
Recent Investors
Financials
$215M
Total Raised
2
Funding rounds
6
Investors